[Market performance].

December 9 to December 13

For the week, the Shanghai Composite Index fell 0.36%, and the Biologics sector fell 1.58%.

Gan & Lee Pharmaceutical rose 0.68% this week, with a total weekly turnover of 1.776 billion yuan, and as of the close of the week, Gan & Lee Pharmaceutical's share price was 46.19 yuan.

[Related information].

The controlling shareholder of Gan & Lee Pharmaceutical released 26.5 million shares

Gan & Lee Pharmaceutical (603087) issued an announcement on the release of part of the shares of the controlling shareholder and actual controller. The controlling shareholder Gan Zhongru holds 34.21% of the company's shares, and recently handled the registration of 26.5 million shares, and after the release of the pledge, Gan Zhongru and his control of Beijing Xute Hongda held a total of 41.82% of the company's total share capital. At present, Gan Zhongru and Xute Hongda have pledged a total of 39.35 million shares, accounting for 15.65% of their holdings and 6.55% of the company's total share capital. The announcement pointed out that the remaining pledged shares of Gan Zhongru are 28.45 million shares, accounting for 13.83% of his shares and 4.73% of the company's total share capital. As of the disclosure date of the announcement, Gan Zhongru's pledged shares are within a controllable range, and there is no risk of liquidation or forced transfer, which will not have a substantial impact on the actual control and operation of the company.

Gan & Lee Pharmaceutical's Phase II clinical trial of innovative re-drug was approved in the United States

On the evening of December 12, Gan & Lee Pharmaceuticals announced that its wholly-owned subsidiary, Gan & Lee Pharmaceuticals USA Corporation, has been approved by the U.S. Food and Drug Administration (hereinafter referred to as "FDA") for phase II clinical trials in the United States. This development marks a key step forward for Gan & Lee Pharmaceuticals in the field of obesity/overweight treatment. According to the latest data released by the World Obesity Federation (WOF) Global Obesity Report (2024), about 2.2 billion adults worldwide were overweight in 2020, accounting for about 42% of the total adult population, and this number is expected to rise to 3.3 billion in 2035.

Gan & Lee Pharmaceutical: GZR18 injection was approved by the US FDA for clinical trials

Gan & Lee Pharmaceutical (603087) announced on the evening of December 12 that its wholly-owned subsidiary, Gan & Lee Pharmaceutical USA, has been approved by the U.S. Food and Drug Administration (FDA) to conduct phase II clinical trials of GZR18 injection. GZR18 injection is a long-acting GLP-1 receptor agonist designed for the treatment of adult adults with type 2 diabetes mellitus and weight management in obese/overweight individuals.

Gan & Lee Pharmaceutical: The cancellation of stock options under the 2021 equity incentive plan has been completed

On the evening of December 10, Gan & Lee Pharmaceutical announced that the company reviewed and approved the "Proposal on Terminating the Implementation of the 2021 Stock Option Incentive Plan and Cancellation of Stock Options", agreeing to terminate the implementation of the 2021 stock option incentive plan and cancel 12,086,237 stock options that have been granted but not yet exercised in the incentive plan. The Company has submitted an application for cancellation of the above-mentioned stock options to the Shanghai subsidiary of China Securities Depository and Clearing Corporation Limited, and the cancellation of the above-mentioned stock options has been completed on December 6, 2024 after the review and confirmation of the Shanghai subsidiary of China Securities Depository and Clearing Corporation Limited.

[Stock price performance of companies in the same industry - biological products].

Code Name: Latest Price: Weekly Change, 10-Day Change, Monthly Change 300142 Watson Biotech13.54 Yuan-7.70%, -8.51%, -8.51%, 688506 Baili Tianheng-U199.80 Yuan, -10.28%, -7.51%, -7.51%, 300122 Zhifei Biotech, 28.80 Yuan, -4.98%, -2.01%, -2.01%, 002252 Shanghai RAAS, 7.50 Yuan, -0.13%, -0.27%, -0.27% 301301 Chuanning Biotech 12.91 yuan -2.93%-2.27%-2.27%.

Source: Finance